



DOI: 10.4274/jcrpe.galenos.2025.2025-6-24
J Clin Res Pediatr Endocrinol 2026;18(2):254-260

Real-World Efficacy of Weekly Somatrogen on Growth and Bone Health in Pediatric Growth Hormone Deficiency: A 12-Month Retrospective Cohort Study

© Mohammad Hosny Awad^{1,2}, © Reham Ghanim¹, © Rania Eladi¹, © Zulf Mughal¹, © Manal Mustafa¹

¹Al Jalila Children's Hospital, Dubai Health, Dubai, United Arab Emirates

²Department of Pediatrics, Mansoura University Children's Hospital, Mansoura, Egypt

Cite this article as: Awad MH, Ghanim R, Eladi R, Mughal Z, Mustafa M. Real-world efficacy of weekly somatrogen on growth and bone health in pediatric growth hormone deficiency: a 12-month retrospective cohort study. J Clin Res Pediatr Endocrinol. 2026;18(2):254-260

ABSTRACT

Objective: Growth hormone deficiency (GHD) in children results in short stature and impaired bone health. While daily growth hormone (GH) injections are effective, they are associated with adherence challenges. Somatrogen, a long-acting, recombinant human GH (rhGH), allows weekly administration, potentially improving treatment compliance.

Methods: This retrospective cohort study included prepubertal children with GHD treated with weekly Somatrogen at Al Jalila Children's Hospital, Dubai. Diagnosis was based on clinical, biochemical, and radiological criteria, including height standard deviation score (SDS) <-2.0, subnormal growth velocity, and subnormal peak GH in one stimulation test (<10 ng/mL), supported by low IGF-1 and/or abnormal cranial magnetic resonance imaging. Growth outcomes and bone health indices were assessed over 12 months using auxology, insulin-like growth factor 1 (IGF-1) levels, and BoneXpert-derived bone health index (BHI) SDS and Metacarpal Index (MCI) SDS.

Results: The study cohort consisted of 39 children with GHD. After 12 months of therapy, mean height SDS improved significantly from -2.16 ± 0.80 to -1.65 ± 0.71 ($p < 0.001$). IGF-1 SDS rose from -1.38 ± 1.02 to 0.88 ± 1.57 ($p < 0.001$). Adult predicted height and BHI SDS also improved significantly ($p = 0.005$ and $p < 0.001$, respectively). No significant changes were observed in bone age SDS or MCI SDS.

Conclusion: Weekly Somatrogen significantly improved linear growth, IGF-1 levels, and measures of cortical bone health without advancing bone age in children with GHD. These findings support the efficacy of this form of long-acting GH therapy and its potential to optimize growth and skeletal outcomes in clinical practice.

Keywords: Growth hormone deficiency, somatrogen, bone health, IGF-1, children

Corresponding Author: Mohammad Hosny Awad, MD, Al Jalila Children's Hospital, Dubai Health, Dubai, United Arab Emirates

E-mail: mo7amed_hosny@mans.edu.eg **ORCID:** orcid.org/0000-0002-9177-6554

Conflict of interest: None declared

Received: 03.07.2025 **Accepted:** 07.09.2025 **Epub:** 30.09.2025 **Publication Date:** 01.07.2026



© Copyright 2026 by Turkish Society for Pediatric Endocrinology and Diabetes / The Journal of Clinical Research in Pediatric Endocrinology published by Galenos Publishing House. Licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License.

What is already known on this topic?

Daily growth hormone (GH) therapy is effective but often limited by poor adherence. Weekly Somatrogen offers a convenient alternative, with early data showing comparable growth outcomes. Effects on bone health as measured by bone age or bone health index (BHI) remain underreported.

What this study adds?

Weekly Somatrogen improved height and insulin-like growth factor 1 standard deviation score over 12 months in prepubertal patients with GH deficiency (GHD). Somatrogen increased BHI without advancing bone age or metacarpal index. Somatrogen appears to be a safe, effective, once-weekly GH-therapy option.

Introduction

Growth hormone deficiency (GHD) in children is characterized by short stature, reduced growth velocity, and failure to achieve normal adult height, negatively impacting quality of life and future outcomes (1,2).

Growth hormone replacement has enabled children with GHD to achieve height within the normal accepted adult range (1). However, agents used for conventional daily growth hormone therapy have a short half-life (3) and require frequent injections (4), which contribute to caregiver burden (5) and poor adherence (6). This leads to frequent missed doses (7) and eventually a poorer clinical outcome (8).

Efforts have focused on developing long-acting GH formulations to improve convenience, reduce injection burden, and enhance clinical outcomes (9,10). Somatrogen (Ngenla®) is a long-acting rhGH with three C-terminal peptide extensions, designed to extend half-life and enable weekly dosing. Clinical trials have demonstrated that Somatrogen achieves growth outcomes comparable to daily GH therapy (11,12).

GHD also impairs bone health, leading to reduced bone mineral density (BMD), as shown by dual-energy X-ray absorptiometry (DXA) (13) and computed tomography studies (14). GH replacement promotes osteoblast activity, new bone formation, and improved BMD (15,16).

The bone health index (BHI), derived from hand radiographs using the automated BoneXpert® software (Visiana ApS, Fremtidsvej 1, 2970 Hørsholm, Denmark), serves as a robust indicator of cortical bone strength in children (17). Prior studies have demonstrated that daily GH treatment is associated with significant improvements in BHI (18).

The metacarpal index (MCI), another parameter generated through radiogrammetry, estimates cortical thickness and has been validated as a predictor of fracture risk (19,20). Both BHI and MCI are calculated from metacarpal dimensions: BHI is defined as the cortical area divided by width^{1.33} multiplied by

length^{0.33}, while MCI is calculated as cortical area divided by width². These indices correlate strongly with DXA findings and provide a reliable, non-invasive means of assessing skeletal integrity in growing children (21,22).

The aim of the present study was to evaluate the real-world effects of weekly Somatrogen therapy on growth outcomes, including height velocity, adult predicted height (APH), and IGF-1 stability, as well as the bone health indices, BHI and MCI, in children with GHD.

We hypothesised that weekly Somatrogen would improve linear growth and bone health in prepubertal children with GHD.

Methods

This retrospective cohort study assessed pre- and post-treatment outcomes over 12 months in children diagnosed with GHD who received Somatrogen therapy at Al Jalila Children's Hospital in Dubai, UAE. The Institutional Review Boards of Al Jalila Children's Hospital and Mohammed Bin Rashid University approved the study. Participants were consecutively recruited from January 2023 to June 2024.

The study population included children who received Somatrogen therapy at a dose of 0.66 mg/kg/week (11), all patients remained on the same dose throughout the 12 months of the study. Their age was between 3.0 and 10.0 years for girls and 3.0 and 11.0 years for boys. All were prepubertal, defined as Tanner stage 1 on physical examination (23,24). All patients remained prepubertal (Tanner stage 1) throughout the entire 12-month study period.

The diagnosis of GHD was established through an integrated approach combining clinical, radiological, and biochemical evidence. An auxological assessment was performed, with growth failure defined as a height standard deviation score (SDS) below -2.0 for age and sex or a growth velocity 1 SD below the mean for chronological age over the 12 months prior to treatment (25,26).

Participants were included if they exhibited a peak GH <10 ng/mL in one stimulation test, supported by either: (1) height

SDS <-2.0 + growth velocity <-1 SDS, or (2) low IGF-1/IGFBP-3 (insulin-like growth factor binding protein-3), or (3) abnormal cranial MRI. This approach is consistent with guidelines for severe phenotypes (27,28).

Exclusion criteria included previous exposure to growth-promoting agents, abnormal thyroid function, or other significant medical conditions. Data was collected anonymously using medical record numbers to ensure confidentiality.

Auxologic Measurements

Height was measured using a wall-mounted stadiometer [Seca216® (Seca GmbH & Co. KG, Hammer Steindamm 9-25, 22089 Hamburg, Germany)]. Height SDS was calculated using CDC 2000 references (29).

Laboratory Investigations

GH measurements were performed using the Siemens Immulite® assay (Siemens Healthineers, Llanberis, Gwynedd, United Kingdom); (sensitivity: 0.01 ng/mL). Serum IGF-1 was measured at baseline and 96 hours after the most recent Somatrogen dose to reflect weekly pharmacokinetics (30) using the Roche Elecsys® ECLIA (Roche Diagnostics GmbH, Sandhofer Strasse 116, 68305 Mannheim, Germany); (range: 0.25-1600 ng/mL; CV<5%) (31). IGF-1 values were expressed as SDS based on age- and sex-specific norms; eligible patients had baseline IGF-1 at least 1 SD below the mean (11,31).

Radiographic Assessments

An automated radiographic analysis of the left hand and wrist radiographs was performed using BoneXpert® software before the initiation of Somatrogen therapy and after 12 months of treatment. This automated analysis determined bone age, BHI, and MCI.

Bone age assessment using the BoneXpert® method is based on the Greulich-Pyle bone age standard, and it analyzes the image completely automatically using artificial intelligence (AI). It has been shown to provide accurate data on a patient's bone age, in addition to analysis of BHI and MCI (32).

BoneXpert® offers an automated assessment of both bone age and cortical bone geometry using radiographic measurements. Specifically, it evaluates the width (W), cortical thickness (T), and length (L) of the second, third, and fourth metacarpal bones. From these parameters, it calculates key indices:

Cortical area (A): Computed using the formula $A=\pi \times W \times T \times (1-T/W)$, representing the area of the cortical bone cross-section.

Metacarpal index (MCI): Defined as $MCI=A/W^2$, this index expresses cortical bone thickness relative to the overall bone width.

Bone health index (BHI): Calculated as $BHI=A/(W^{1.33} \times L^{0.33})$, this index integrates bone dimensions to reflect cortical bone robustness.

These indices provide a detailed profile of cortical bone structure and are interpreted against standardized reference values for bone age. Although BoneXpert's normative dataset is based on Caucasian populations (33), it remains the most widely validated tool for pediatric skeletal assessment. To mitigate ethnic bias, we report results as SDS relative to each patient's bone age rather than relying on raw values.

APH was calculated using BoneXpert® software, which applies the Bayley-Pinneau method to deliver accurate and standardized predictions of final adult height, minimizing variability associated with manual calculations (34).

Sample Size

The sample size was calculated based on Horikawa et al. (11) study, in which Somatrogen increased height SDS in children with GHD by 0.94 after 12 months of treatment. Therefore, at a significance level of 0.05 and power of 80%, a total of 30 subjects were required to test our hypothesis.

Ethical Considerations

This study was approved by the Dubai Scientific Research Ethics Committee (DSREC), Dubai Health Authority, and the Institutional Review Board of Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU IRB-2024-562; Ref: DSREC-SR-11/2024_04). Given the retrospective design, the requirement for informed consent was waived.

Statistical Analysis

Statistical analysis was done using SPSS, version 29 (IBM, Armonk, NY, USA). Continuous variables were assessed for normality using Shapiro-Wilk tests. Paired t-tests compared pre/post outcomes for parametric data. Continuous variables were summarized as means with SDs and/or medians with minimum and maximum values, as appropriate. Categorical data were presented as frequencies and percentages within the study cohort. To assess the primary endpoint, annual height velocity, comparisons between baseline and the end of therapy were conducted using a t-test, with statistical significance set at a *p*-value of less than 0.05.

Results

The study included 39 patients with a mean age of 9.63 years, of whom 64% were male (Table 1). Height SDS improved significantly from a mean of -2.16 ± 0.80 at baseline to -1.65 ± 0.71 after 12 months of treatment ($p < 0.001$) (Figure 1). When analysed separately by sex, both boys and girls demonstrated a similar

and significant increase in absolute height over 12 months. In boys (n=27), mean height increased from 123.73±8.74 cm to 132.06±8.55 cm (mean change +8.33 cm, p<0.001). In girls (n=12), mean height increased from 122.23 ± 14.88 cm to 130.97±13.82 cm (mean change +8.73 cm, p<0.001).

APH improved from 161.86±7.2 cm to 164.88±6.4 cm (p<0.001) (Figure 2). Bone age SDS showed no change (p=0.269) (Table 2).

The IGF-1 SDS improved significantly from a mean of -1.38±1.02

at baseline to 0.88±1.57 after treatment (p<0.001) (Figure 3). BHI SDS improved from -1.29±1.50 to -0.83±1.41 (Δ= +0.46; p<0.001). MCI SDS showed no significant change (-1.33±1.18 to -1.16 ±1.07; Δ= +0.17; p=0.106) (Table 2).

Table 1. Characteristics of patients in the study at baseline	
Number	39
Age, years Mean±SD	9.63±2.19
Males n (%)	27 (64)
Bone age, years Mean±SD	7.5±2.37
Bone age SDS Mean±SD	-1.53±1.30
Mean height SDS Mean±SD	-2.16± 0.80
Mean APH, cm Mean±SD	161.73± 7.60

APH: adult predicted height; N: number; SDS: standard deviation score.




Figure 2. Change in adult predicted height (APH) before and after 12 months of weekly Somatrogen therapy in children with growth hormone deficiency. p<0.001.




Figure 1. Change in height SDS before and after 12 months of weekly Somatrogen therapy in children with growth hormone deficiency. p<0.001.
SDS, standard deviation score.




Figure 3. Change in IGF-1 SDS before and after Somatrogen treatment. p<0.001.
IGF-1, insulin-like growth factor-1; SDS, standard deviation score.

Table 2. Effect of Somatrogen on bone geometry after 12 months of treatment			
Variable	Baseline (Mean±SD)	After 12 months of Somatrogen treatment (Mean±SD)	p value
Bone age SDS	-1.53±1.30	-1.44±1.28	0.269
BHI SDS	-1.29±1.50	-0.83±1.41	<0.001
MCI SDS	-1.33±1.18	-1.16±1.07	0.106

p values calculated using paired t-tests comparing baseline and 12-month post-treatment values.
BHI: bone health index; MCI: metacarpal index; SDS: standard deviation score.

Discussion

In our real-world setting, treatment with Somatrogen significantly increased height SDS, APH, and IGF-1 SDS levels after one year of treatment. In addition, Somatrogen treatment for one year was associated with improved BHI without significant change in bone age or MCI.

The significant height SDS gain observed aligns with findings from Deal et al. (12), where Somatrogen demonstrated non-inferiority to daily somatotropin in terms of height velocity and height SDS with the least squares mean (LS mean) treatment difference: 0.06 (95% confidence interval, -0.01, 0.13). Horikawa et al. (11) similarly reported robust growth outcomes with Somatrogen in rhGH naïve prepubertal children where the LS mean change in height SDS from baseline to 12 months was greater in the Somatrogen group (0.94) compared to the daily GH group (0.52) (11). Our height SDS improvement ($\Delta 0.51$) closely mirrors daily GH outcomes in Deal et al. (12) ($\Delta 0.52$).

The observed increase in IGF-1 SDS in our cohort is consistent with previous findings. Deal et al. (12) reported similar findings, noting that IGF-1 profiles with Somatrogen were higher compared to daily GH regimens, where the mean IGF-1 SDS was -1.95 at baseline and increased to 0.65 at 12 months post-baseline. Similarly, Horikawa et al. (11) reported significant increase in IGF-1 SDS in Japanese children with GHD after treatment with Somatrogen (11). Improvements in BHI observed in our study with Somatrogen treatment are consistent with findings from Wydra et al. (35), which emphasized the anabolic effects of GH on bone mineralization. Another study showed that in short-statured children, daily GH treatment significantly improved BHI, where BHI SDS increased from -0.97 to -0.17 after 1 year of GH ($p < 0.001$). The BHI increased initially with GH treatment and plateaued over time, suggesting sustained improvement in bone health (18).

The absence of significant bone age advancement in our study differs from results commonly observed with previous studies, where Deal et al. (12) in a phase 3 study comparing Somatrogen to daily rhGH found significant bone age progression after one year of treatment, which was comparable to bone age progression rates seen on daily rhGH. Similarly, Horikawa et al. (11) reported significant bone age advancement on Somatrogen treatment. This discrepancy may be explained by the different methods used to assess bone age. In our study, bone age was determined using an automated AI-based analysis, whereas the previous studies relied on manual evaluation.

However, the lack of significant improvement in the MCI was notable. This is consistent with findings from Bettendorf et al. (36) and Radetti et al. (37), which reported no substantial alteration in metacarpal proportions during GH therapy.

However, the findings diverge from Martin et al. (38), who also used BoneXpert and observed significant improvement in MCI within the first year of daily GH therapy (22). The discrepancy with the results reported by Martin et al. (38) could stem from differences in GH regimens. Daily GH therapy may exert a more consistent anabolic effect on bone geometry compared to the intermittent stimulation provided by weekly Somatrogen.

While BoneXpert software represents a validated and widely-used automated tool for bone health assessment in pediatric populations, it is important to acknowledge that its reference standards are derived from a Dutch Caucasian population (33). To address this potential limitation in our ethnically diverse cohort, we employed SDS relative to bone age rather than absolute values, a recommended approach that helps normalize for population differences (39). Although ethnic variations in BMD and skeletal architecture have been documented in pediatric populations, BoneXpert has demonstrated acceptable performance and has undergone validation across diverse populations (40). The BHI provided by BoneXpert has been shown to reflect cortical BMD effectively in pediatric and adolescent patients (17), and the use of SDS values in our analysis provides a standardized approach that accounts for individual variation, allowing for meaningful clinical interpretation of bone health parameters (38). While population-specific reference data would be ideal for Middle Eastern children, BoneXpert remains the most extensively validated automated tool available for pediatric bone health assessment, and our findings using SDS-based analysis provide valuable real-world evidence of skeletal outcomes following Somatrogen therapy (41). In addition, the paired design of our analysis, where each participant served as their own control, further mitigates the influence of any systematic bias in the reference data.

The observed improvement in the BHI, despite the absence of significant changes in the MCI or bone age, suggests a nuanced shift in cortical bone geometry. Given that MCI is calculated as the ratio of cortical area (A) to the square of bone width (W^2), its stability implies that any increase in cortical area occurred proportionally to changes in bone width. In contrast, BHI incorporates both width and bone length in the denominator with lower exponents ($W^{1.33}$ and $L^{0.33}$), making it more sensitive to subtle increases in cortical area. The improvement in BHI, therefore, likely reflects a disproportionate increase in cortical thickness relative to width, resulting in a net gain in cortical area that was not substantial enough to affect MCI. Moreover, the lack of advancement in bone age suggests that these structural changes occurred independently of accelerated skeletal maturation.

Study Limitations

This study has several limitations. Its retrospective cross-sectional design, absence of a daily GH control group, and relatively small

sample size may restrict the generalizability of the results. DXA, the gold standard for assessing BMD, was not employed (42). Bone age assessments were conducted using BoneExpert, which, while the most practical and validated tool available in the absence of local reference data, may be less accurate in a cohort with diverse ethnic backgrounds (33). In addition, systematic safety data were not collected due to the retrospective nature of the study.

Conclusion

In a real-world setting, the results of our study add to the growing body of evidence showing that Somatrogen is an effective option for GHD treatment. Weekly Somatrogen therapy led to significant improvements in growth parameters and IGF-1 levels, as well as enhancements in the BHI. However, the nuanced effects on cortical bone geometry underscore the need for further research. Future studies should include the assessment of bone health using DXA to provide a more comprehensive evaluation of skeletal outcomes.

Ethics

Ethics Committee Approval: This study was approved by the Dubai Scientific Research Ethics Committee (DSREC), Dubai Health Authority, and the Institutional Review Board of Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU IRB-2024-562; Ref: DSREC-SR-11/2024_04).

Informed Consent: Given the retrospective design, the requirement for informed consent was waived.

Footnotes

Authorship Contributions

Concept: Mohammad Hosny Awad, Rania Eladl, Zulf Mughal, Manal Mustafa, Design: Mohammad Hosny Awad, Rania Eladl, Zulf Mughal, Manal Mustafa, Data Collection or Processing: Mohammad Hosny Awad, Reham Ghanim, Rania Eladl, Zulf Mughal, Manal Mustafa, Analysis or Interpretation: Mohammad Hosny Awad, Manal Mustafa, Literature Search: Mohammad Hosny Awad, Manal Mustafa, Writing: Mohammad Hosny Awad, Manal Mustafa.

Financial Disclosure: There is no specific funding related to this research.

References

1. Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-i treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-i deficiency. *Horm Res Paediatr*. 2016;86:361-397. Epub 2016 Nov 25
2. Backeljauw P, Cappa M, Kiess W, Law L, Cookson C, Sert C, Whalen J, Dattani MT. Impact of short stature on quality of life: a systematic literature review. *Growth Horm IGF Res*. 2021;57-58:101392. Epub 2021 Apr 30
3. Høybye C, Cohen P, Hoffman AR, Ross R, Biller BM, Christiansen JS; Growth Hormone Research Society. Status of long-acting-growth hormone preparations--2015. *Growth Horm IGF Res*. 2015;25:201-206. Epub 2015 Jul 14
4. Saenger PH, Mejia-Corletto J. Long-Acting Growth Hormone: An Update. *Endocr Dev*. 2016;30:79-97. Epub 2015 Dec 10
5. Acerini CL, Segal D, Criseno S, Takasawa K, Nedjati N, Röhrich S, Maghnie M. Shared decision-making in growth hormone therapy-implications for patient care. *Front Endocrinol (Lausanne)*. 2018;9:688.
6. Miller BS, Velazquez E, Yuen KCJ. Long-acting growth hormone preparations - current status and future considerations. *J Clin Endocrinol Metab*. 2020;105:e2121-e2133. Erratum in: *J Clin Endocrinol Metab*. 2021;106:e4793.
7. van Dommelen P, Koledova E, Wit JM. Effect of adherence to growth hormone treatment on 0-2 year catch-up growth in children with growth hormone deficiency. *PLoS One*. 2018;13:e0206009.
8. Cutfield WS, Derraik JG, Gunn AJ, Reid K, Delany T, Robinson E, Hofman PL. Non-compliance with growth hormone treatment in children is common and impairs linear growth. *PLoS One*. 2011;6:e16223.
9. Marni C, Orso M, Calcaterra V, Wasniewska MG, Aversa T, Granato S, Bruschini P, Guadagni L, d'Angela D, Spandonaro F, Polistena B, Zuccotti G. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis. *Pharmacol Res*. 2023;193:106805. Epub 2023 May 24
10. Loftus J, Wogen J, Oliveri D, Benjumea D, Jhingran P, Chen Y, Alvir J, Rivero-Sanz E, Kowalik JC, Wajnrajch MP. Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in the UK. *Front Endocrinol (Lausanne)*. 2022;13:1014743.
11. Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG, Hoshino Y, Okayama A, Shima D, Gomez R, Pastrak A, Castellanos O. Efficacy and safety of once-weekly somatrogen compared with once-daily somatropin (Genotropin®) in Japanese children with pediatric growth hormone deficiency: results from a randomized phase 3 study. *Horm Res Paediatr*. 2022;95:275-285. Epub 2022 Apr 13
12. Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, Kim HS, Ko C, Malievskiy O, Cara JF, Roland CL, Taylor CT, Valluri SR, Wajnrajch MP, Pastrak A, Miller BS. Efficacy and safety of weekly somatrogen vs daily somatropin in children with growth hormone deficiency: a phase 3 study. *J Clin Endocrinol Metab*. 2022;107:e2717-e2728.
13. Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. *J Clin Endocrinol Metab*. 1992;74:118-123.
14. Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE, Shalet SM. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. *Clin Endocrinol (Oxf)*. 1995;42:627-633.
15. Stamoyannou L, Karachaliou F, Giourelis E, Voskaki E, Mengreli C, Bartsocas CS, Koutselinis A. Effect of growth hormone therapy on bone metabolism of growth hormone deficient children. *Eur J Pediatr*. 1997;156:592-596.
16. Saggese G, Baroncelli GI, Bertelloni S, Barsanti S. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. *J Clin Endocrinol Metab*. 1996;81:3077-3083.
17. Schündeln MM, Marschke L, Bauer JJ, Hauffa PK, Schweiger B, Führer-Sakel D, Lahner H, Poeppel TD, Kiewert C, Hauffa BP, Grasemann C. A piece of the puzzle: the bone health index of the bonexpert software reflects cortical bone mineral density in pediatric and adolescent patients. *PLoS One*. 2016;11:e0151936.

18. Holzapfel L, Choukair D, Schenk JP, Bettendorf M. Longitudinal assessment of bone health index as a measure of bone health in short-statured children before and during treatment with recombinant growth hormone. *J Pediatr Endocrinol Metab.* 2023;36:824-831.
19. Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, El-Hajj Fuleihan G, Kecskemethy HH, Jaworski M, Gordon CM; International Society for Clinical Densitometry. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. *J Clin Densitom.* 2014;17:225-242. Epub 2014 Mar 29
20. Haara M, Heliövaara M, Impivaara O, Arokoski JP, Manninen P, Knekt P, Kärkkäinen A, Reunanen A, Aromaa A, Kröger H. Low metacarpal index predicts hip fracture: a prospective population study of 3,561 subjects with 15 years of follow-up. *Acta Orthop.* 2006;77:9-14.
21. Vogiatzi MG, Davis SM, Ross JL. Cortical bone mass is low in boys with klinefelter syndrome and improves with oxandrolone. *J Endocr Soc.* 2021;4:bvab016.
22. Growth Hormone Effects on Metacarpal Bone Geometry and Bone Age in Growth Hormone-Deficient Children | ESPE2019 | 58th Annual ESPE | ESPE Abstracts [Internet]. [cited 2024 May 14]. Available from: <https://abstracts.eurospe.org/hrp/0092/hrp0092rfc2.3>
23. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. *Arch Dis Child.* 1969;44:291-303.
24. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. *Arch Dis Child.* 1970;45:13-23.
25. Hage C, Gan HW, Ibba A, Patti G, Dattani M, Loche S, Maghnie M, Salvatori R. Advances in differential diagnosis and management of growth hormone deficiency in children. *Nat Rev Endocrinol.* 2021;17:608-624. Epub 2021 Aug 20
26. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. *GH Research Society. J Clin Endocrinol Metab.* 2000;85:3990-3993.
27. Yau M, Rapaport R. Growth hormone stimulation testing: to test or not to test? That is one of the questions. *Front Endocrinol (Lausanne).* 2022;13:902364.
28. Ibba A, Loche S. Diagnosis of GH Deficiency Without GH Stimulation Tests. *Front Endocrinol (Lausanne).* 2022;13:853290.
29. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. *Pediatrics.* 2002;109:45-60.
30. Nayak S, Wajnrajch MP, Korth-Bradley J, Taylor CT, Thomas M, Maniatis A, Deal CL, Rosenfeld RG, Cara JF, Ravva P. IGF-1 assessment during weekly somatogon treatment in pediatric patients with GH deficiency. *J Endocr Soc.* 2025;9:bvaf001.
31. ROCHE - eLabDoc [Internet]. [cited 2025 Apr 8]. Available from: https://elabdoc-prod.roche.com/eLD/web/global/en/documents?ffDocumentTypes=endt_method_sheet&productNumber=CPS_000488&searchType=Keyword&sourceSearchType=Keyword&keywordFilterCatalogNumbers=07475918190,,07475896190
32. Thodberg HH, Thodberg B, Ahlkvist J, Offiah AC. Autonomous artificial intelligence in pediatric radiology: the use and perception of BoneXpert for bone age assessment. *Pediatr Radiol.* 2022;52:1338-1346. Epub 2022 Feb 28
33. Thodberg HH, van Rijn RR, Tanaka T, Martin DD, Kreiborg S. A paediatric bone index derived by automated radiogrammetry. *Osteoporos Int.* 2010;21:1391-1400. Epub 2009 Nov 24
34. Thodberg HH, Jenni OG, Cafilisch J, Ranke MB, Martin DD. Prediction of adult height based on automated determination of bone age. *J Clin Endocrinol Metab.* 2009;94:4868-4874. Epub 2009 Nov 19
35. Wydra A, Czajka-Oraniec I, Wydra J, Zgliczyński W. The influence of growth hormone deficiency on bone health and metabolisms. *Reumatologia.* 2023;61:239-247. Epub 2023 Aug 31
36. Bettendorf M, Graf K, Nelle M, Heinrich UE, Tröger J. Metacarpal index in short stature before and during growth hormone treatment. *Arch Dis Child.* 1998;79:165-168.
37. Radetti G, Buzi F, Paganini C, Martelli C, Adami S. A four year dose-response study of recombinant human growth hormone treatment of growth hormone deficient children: effects on growth, bone growth and bone mineralization. *Eur J Endocrinol.* 2000;142:42-46.
38. Martin DD, Heckmann C, Neuhof J, Jenni OG, Ranke MB, Binder G. Comparison of radiogrammetrical metacarpal indices in children and reference data from the First Zurich Longitudinal Study. *Pediatr Radiol.* 2012;42:982-991. Epub 2012 Jun 6
39. Bachrach LK, Hastie T, Wang MC, Narasimhan B, Marcus R. Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study. *J Clin Endocrinol Metab.* 1999;84:4702-4712.
40. Maratova K, Zemkova D, Sedlak P, Pavlikova M, Amaratunga SA, Krasnicanova H, Soucek O, Sumnik Z. A comprehensive validation study of the latest version of BoneXpert on a large cohort of Caucasian children and adolescents. *Front Endocrinol (Lausanne).* 2023;14:1130580.
41. Alshamrani K, Messina F, Bishop N, Offiah AC. Estimating bone mass in children: can bone health index replace dual energy x-ray absorptiometry? *Pediatr Radiol.* 2019;49:372-378. Epub 2018 Nov 24
42. Kalkwarf HJ, Shepherd JA, Fan B, Sahay RD, Ittenbach RF, Kelly A, Yolton K, Zemel BS. Reference ranges for bone mineral content and density by dual energy X-ray absorptiometry for young children. *J Clin Endocrinol Metab.* 2022;107:E3887-3900.